Carlos A Camargo1, R Graham Barr2, Rong Chen3, Frank E Speizer3. 1. Channing Laboratory, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: ccamargo@partners.org. 2. Columbia University Medical Center, New York, NY. 3. Channing Laboratory, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: Therapy with inhaled corticosteroids (ICSs) decreases the risk of asthma exacerbations. Recent studies have suggested that ICS therapy also may decrease the risk of cardiovascular disease, and perhaps of all-cause mortality. We examined this hypothesis in a large, well-characterized cohort of asthmatic women. METHODS: In 1976, the Nurses' Health Study enrolled 121,700 registered nurses, who were 30 to 55 years of age. Participants were asked about "physician-diagnosed asthma" on biennial questionnaires. In 1998, asthmatic participants were sent a supplementary questionnaire on asthma diagnosis and management, including ICS use. Mortality was assessed through 2003, without knowledge of the 1998 (baseline) ICS status. The odds ratios (ORs) for death were adjusted for age, asthma severity, smoking, heart disease, cancer, stroke, aspirin, and statin use. RESULTS: Among 2,671 eligible women (ie, those who responded to the 1998 supplement [85%], met criteria for persistent asthma, and had not received a prior diagnosis of COPD), 54% reported ICS use. Over the next 5 years, 87 women (3.3%) died (cardiovascular deaths, 22; cancer deaths, 31; other, 34 [including 4 from asthma]). Compared to asthmatic women who did not use ICSs, those receiving therapy with ICSs had lower all-cause mortality (OR, 0.58; 95% confidence interval [CI], 0.36 to 0.92). ICS users were at significantly lower risk of cardiovascular death (OR, 0.35; 95% CI, 0.13 to 0.93), but not of death from cancer (OR, 0.66; 95% CI, 0.32 to 1.38) or other causes (OR, 0.62; 95% CI, 0.30 to 1.27). CONCLUSIONS: ICS use was associated with significantly lower cardiovascular and all-cause mortality in women with asthma. These observational data suggest that ICSs may indeed have antiinflammatory benefits beyond the airway, which is a possibility that merits further study.
BACKGROUND: Therapy with inhaled corticosteroids (ICSs) decreases the risk of asthma exacerbations. Recent studies have suggested that ICS therapy also may decrease the risk of cardiovascular disease, and perhaps of all-cause mortality. We examined this hypothesis in a large, well-characterized cohort of asthmatic women. METHODS: In 1976, the Nurses' Health Study enrolled 121,700 registered nurses, who were 30 to 55 years of age. Participants were asked about "physician-diagnosed asthma" on biennial questionnaires. In 1998, asthmatic participants were sent a supplementary questionnaire on asthma diagnosis and management, including ICS use. Mortality was assessed through 2003, without knowledge of the 1998 (baseline) ICS status. The odds ratios (ORs) for death were adjusted for age, asthma severity, smoking, heart disease, cancer, stroke, aspirin, and statin use. RESULTS: Among 2,671 eligible women (ie, those who responded to the 1998 supplement [85%], met criteria for persistent asthma, and had not received a prior diagnosis of COPD), 54% reported ICS use. Over the next 5 years, 87 women (3.3%) died (cardiovascular deaths, 22; cancer deaths, 31; other, 34 [including 4 from asthma]). Compared to asthmatic women who did not use ICSs, those receiving therapy with ICSs had lower all-cause mortality (OR, 0.58; 95% confidence interval [CI], 0.36 to 0.92). ICS users were at significantly lower risk of cardiovascular death (OR, 0.35; 95% CI, 0.13 to 0.93), but not of death from cancer (OR, 0.66; 95% CI, 0.32 to 1.38) or other causes (OR, 0.62; 95% CI, 0.30 to 1.27). CONCLUSIONS:ICS use was associated with significantly lower cardiovascular and all-cause mortality in women with asthma. These observational data suggest that ICSs may indeed have antiinflammatory benefits beyond the airway, which is a possibility that merits further study.
Authors: Aysefa Doganci; Tatjana Eigenbrod; Norbert Krug; George T De Sanctis; Michael Hausding; Veit J Erpenbeck; El-Bdaoui Haddad; Hans A Lehr; Edgar Schmitt; Tobias Bopp; Karl-J Kallen; Udo Herz; Steffen Schmitt; Cornelia Luft; Olaf Hecht; Jens M Hohlfeld; Hiroaki Ito; Norihiro Nishimoto; Kazuyuki Yoshizaki; Tadamitsu Kishimoto; Stefan Rose-John; Harald Renz; Markus F Neurath; Peter R Galle; Susetta Finotto Journal: J Clin Invest Date: 2005-02 Impact factor: 14.808
Authors: Matthew C Tattersall; Mengye Guo; Claudia E Korcarz; Adam D Gepner; Joel D Kaufman; Kiang J Liu; R Graham Barr; Kathleen M Donohue; Robyn L McClelland; Joseph A Delaney; James H Stein Journal: Arterioscler Thromb Vasc Biol Date: 2015-04-23 Impact factor: 8.311
Authors: Osman Bektaş; Zeki Yüksel Günaydin; Ahmet Karagöz; Recep Akgedik; Adil Bayramoğlu; Ahmet Kaya Journal: Cardiovasc J Afr Date: 2017 May/Jun Impact factor: 1.167
Authors: Michał Podgórski; Maciej Kupczyk; Piotr Grzelak; Małgorzata Bocheńska-Marciniak; Michał Polguj; Piotr Kuna; Ludomir Stefańczyk Journal: Med Sci Monit Date: 2017-11-09
Authors: Jasper H Kappen; Elisabeth F C van Rossum; Jan A Witte; Gert-Jan Braunstahl; Wouter J B Blox; Susan C van 't Westeinde; Johannes C C M In 't Veen Journal: BMC Pulm Med Date: 2022-02-05 Impact factor: 3.317
Authors: Jose Gregorio Soto-Campos; Vicente Plaza; Joan B Soriano; Carlos Cabrera-López; Carlos Almonacid-Sánchez; Rosa Vazquez-Oliva; Jose Serrano; Aitor Ballaz-Quincoces; Alicia Padilla-Galo; Vanessa Santos Journal: BMC Pulm Med Date: 2013-12-10 Impact factor: 3.317
Authors: Domenico Di Raimondo; Gaia Musiari; Alida Benfante; Salvatore Battaglia; Giuliana Rizzo; Antonino Tuttolomondo; Nicola Scichilone; Antonio Pinto Journal: Int J Environ Res Public Health Date: 2020-09-22 Impact factor: 3.390